Navigation Links
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
Date:1/26/2010

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera is completing a Phase 2A study of AEG33773 in diabetic neuropathic pain and is working with its partner Human Genome Sciences (HGSI) to progress HGS1029 through early stage clinical development. Additional information on these programs can be found on Aegera's website at www.aegera.com.

SOURCE AEGERA THERAPEUTICS INC.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/25/2014)... 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will release ... 30, 2014, after market close on Thursday, August 14, 2014 ... the market opening on Friday, August 15, 2014, at 8:00 ... Standard Time) to review the Company,s financial results and provide ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
...  Amgen (NASDAQ: AMGN ) today announced that it ... results on Thursday, Jan. 26, 2012 after the close of ... conference call with the investment community at 2:00 p.m. Pacific ... Kevin Sharer, chairman and chief executive officer, and other members ...
... SPO Medical Inc. ( SPOM ), a ... in portable monitoring devices, announced today an update to ... strategy for fiscal 2012 primarily based on the completion ... consumer wellness devices. SPO currently has three ...
... team have shown that they can prevent, or even reverse, ... dogs. The disease in humans and dogs is caused ... severe and progressive vision loss. It is one of the ... "Every single abnormal feature that defines the disease in ...
Cached Biology Technology:Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results 2SPO Updates Shareholders on 2012 Corporate Strategy 2SPO Updates Shareholders on 2012 Corporate Strategy 3Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 2Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 3
(Date:7/27/2014)... -- Microorganisms like bacteria and fungi can evade treatment ... or antifungal drugs. These permanent mutations were once thought ... evolve. Now a new study has shown that microorganisms ... known as epimutations -- to gain the benefits of ... mechanism was discovered in a fungus called Mucor circinelloides, ...
(Date:7/27/2014)... data from over 18,000 patients, scientists have identified ... in Parkinson,s disease, including six that had not ... Nature Genetics , was partially funded by the ... scientists working in NIH laboratories. , "Unraveling the ... the multiple mechanisms involved in this complex disease, ...
(Date:7/25/2014)... and some of the smoke from those fires is drifting ... the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua satellite ... over the Great Lakes region of the United States. ... 23, 2014 (first image feature highlighted below) clearly shows the ... In the image, it is over Manitoba and parts ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... relatively new phenomenon in shopping, digital coupons show great ... and usability of a specific type of electronic coupon ... team has found some interesting and important preliminary findings ... used them, why they used them and what problems ...
... of Pennsylvania say that species are still accumulating on ... past. In the study, published in the journal ... computational approach to infer the dynamics of species diversification ... nine patterns of diversification as alternative models, they examined ...
... This release is available in Spanish . ... known as hardening of the arteries, according to results ... with laboratory mice. The research provides the first direct ... lesions, symptomatic of atherosclerosis, from increasing in size in ...
Cached Biology News:Impending death for paper coupons? 2Impending death for paper coupons? 3Penn biologists say species accumulate on Earth at slower rates than in the past 2Blueberries help fight artery hardening, lab animal study indicates 2
... N. Fernandez and G. Butcher (1998). ... subject of much research in the immunology ... structure of MHC proteins and in their ... are now faced with the prospect of ...
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
Biology Products: